Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel

Heart

Volumn 98, Issue 2, 2012, Pages 100-108

  Zabalza, Michel ^a   Subirana, Isaac ^b,c   Sala, Joan ^a,d   Lluis Ganella, Carla ^c   Lucas, Gavin ^c   Tomás, Marta ^c   Masiá, Rafel ^a   Marrugat, Jaume ^c   Brugada, Ramon ^a,d,e   Elosua, Roberto ^b,c  

^a HOSPITAL JOSEP TRUETA   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^d UNIVERSITY OF GIRONA   (Spain)

^e Cardiovascular Genetics Center   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19;

ALLELE; BLEEDING; CONFIDENCE INTERVAL; CORONARY ARTERY DISEASE; CYP2C19 GENE; GENE; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; STENT THROMBOSIS; SYSTEMATIC REVIEW;

ARYL HYDROCARBON HYDROXYLASES; CORONARY ARTERY DISEASE; GENOTYPE; HEMORRHAGE; HUMANS; PHARMACOGENETICS; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; RISK FACTORS; TICLOPIDINE;

EID: 84155167902     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2011.227652     Document Type: Review

References (42)

1. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502. [Erratum published in N Engl J Med 2001;345:1506]. (Pubitemid 32758501)
2. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179-89. (Pubitemid 40397259)
3. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2008;117:261-95. [Erratum, Circulation 2008;117(6):e161].
4. Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 2006;27:647-54.
5. Bliden KP, Dichiara J, Tantry US, et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol 2007;49:657-66. (Pubitemid 46205039)
6. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007;49:1505-16. (Pubitemid 46517957)
7. Savi P, Combalbert J, Gaich C, et al. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost 1994;72:313-17. (Pubitemid 24251300)
8. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000;84:891-6.
9. Hollopeter G, Jantzen HM, Vincent D, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001;409:202-7. (Pubitemid 32144286)
10. Kim KA, Park PW, Hong SJ, et al. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther 2008;84:236-42.
11. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354-62.
12. Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006;108:2244-7. (Pubitemid 44497506)
13. Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007;5:2429-36. (Pubitemid 350154353)
14. Frere C, Cuisset T, Morange PE, et al. Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am J Cardiol 2008;101:1088-93.
15. Sofi F, Giusti B, Marcucci R, et al. Cytochrome P450 2C19(*)2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J 2011;11:199-206.
16. Jin B, Ni HC, Shen W, et al. Cytochorme P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel. Mol Biol Rep 2011;38:1697-702.
17. Hulot JS, Collet JP, Silvain J, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol 2010;56:134-43.
18. Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI. JAMA 2010;304:1821-30.
19. Little J, Higgins JPT, Ionnidis JPA, et al. Strengthening the reporting of genetic association studies (STREGA): an extension of the STROBE statement. Ann Intern Med 2009;150:206-15.
20. Lluís-Ganella C, Lucas G, Subirana I, et al. Qualitative assessment of previous evidence and an updated meta-analysis confirms lack of association between the ESR1 rs2234693 (PvuII) variant and coronary heart disease in men and women. Atherosclerosis 2009;207:480-6.
21. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88. (Pubitemid 17189972)
22. Berkey CS, Hoaglin DC, Mosteller F, et al. A random-effects regression model for meta-analysis. Statistics in Medicine 1995;14:395-411.
23. Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P450 2C19 681G-A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or baremetal stents. J Am Coll Cardiol 2008;51:1925-34. (Pubitemid 351636443)
24. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009;302:849-57.
25. Giusti B, Gori AM, Marcucci R, et al. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics 2007;17:1057-64. (Pubitemid 351339490)
26. Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 2009;30:916-22.
27. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009;373:309-17.
28. Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010;376:1312-19.
29. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363-75.
30. Paré G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 2010;363:1704-14.
31. Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010;376:1320-8.
32. Tiroch KA, Sibbing D, Koch W, et al. Protective effect of the CYPC19*17 polymorphism with increased activation of clopidogrel on cardiovascular events. Am Heart J 2010;160:506-12.
33. Harmsze AM, van Werkum JW, Ten Berg JM, et al. CYP2C19*2 and CYP2C19*3 alleles are associated with stent trombosis: a case-control study. Eur Heart J 2010;31:3046-53.
34. Brackbill ML, Kidd RS, Abdoo AD, et al. Frequency of CYP3A4, CYP3A5, CYP2C9, and CYP2C19 variant alleles in patients receiving clopidogrel that experience repeat acute coronary syndrome. Heart Vessels 2009;24:73-8.
35. Malek LA, Kisiel B, Spiewak M, et al. Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel. Circ J 2008;72:1165-9. (Pubitemid 351957086)
36. Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010;121:512-18.
37. FDA Drug Safety Communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm190836.htm (accessed 3 Aug 2010).
38. Holmes DR Jr, Dehmer GJ, Kauls S, et al. ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA "Boxed Warning". Circulation 2010;122:537-57.
39. Chanock SJ, Manolio T, Boehnke M, et al. NCI-NHGRI Working Group on Replication in Association Studies. Replicating genotype-phenotype associations. Nature 2007;447:655-60. (Pubitemid 46889722)
40. Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochorme P450 enzymes envolved in the two oxidative stops in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010;38:92-9.
41. Gensch C, Hoppe U, Böhm M, et al. Late-breaking clinical trials presented at the American Heart Association Congress in Chicago 2010. Clin Res Cardiol 2011;100:1-9.
42. Bonello L, de Labriolle A, Scheinowitz M, et al. Emergence of the concept of platelet reactivity monitoring of response to thienopyridines. Heart 2009;95:1214-19.